Following the JCVI draft publication of the recommended seasonal influenza vaccines for the 2021/22 winter programme, NHSE have now published a letter with details for those vaccines eligible for reimbursement.
Vaccines reimbursed as part of the NHS Seasonal Influenza Immunisation Programme 2021/22
The following JCVI-recommended vaccines will be reimbursed as part of the NHS Annual Influenza Vaccination Programme for adults in 2021/22.
|Those aged 65 years and over||At-risk adults, including pregnant women, aged 18 to less than 65 years|
• QIVc (where aQIV is not available)
• QIVe (where QIVc is not available)
JCVI considered the use of QIV-HD in those aged 65. However, because of a significantly higher list price QIV-HD is not eligible for reimbursement under the NHS Annual Influenza Vaccination programme for 2021/22.
JCVI also considered the use of QIVr in both those aged over 65 and those aged 18 to 64. However, it is not eligible for reimbursement under the NHS Annual Influenza Vaccination programme for 2021/22 at this stage. Further guidance may be issued on this vaccine.
March 2021 - Update on reimbursement from the BMA
The BMA are aware that prior to the publication of the flu letter for the 2021/22 programme (as above), some practices had already placed orders for QIVe vaccines for their 18-64 year old cohort, and are now struggling to change their orders to QIVc as set out in the flu letter. NHS England and NHS Improvement have now confirmed that, given that QIVe is still recommended for the 18-64 at risk cohort, practices should feel confident that they will be reimbursed for any QIVe administered to this group over the 21/22 season if unable to change their orders.
If any practices have difficulties with reimbursement then please contact the LMC office for escalation to the BMA.
Influenza vaccines for eligible children are centrally procured by Public Health England and are supplied free of charge via ImmForm. These vaccines will NOT be reimbursed as part of the NHS Annual Influenza Vaccination Programme.
|All children aged from 2 years old to those in school year 6, and children in clinical risk groups aged 2 to <18 years||Children aged 6 months to less than 2 years in clinical risk groups (for whom LAIV and QIVc are not licensed)|
• QIVc (if contraindicated to LAIV)